Dedicated to making life better for people suffering from rare diseases with few or no treatment options

Leveraging our proprietary, autologous fibroblast technology platform to create personalized therapies for localized treatments targeting the underlying cause of disease

Expanding our in-house cGMP operation to support a robust pipeline of innovative cell-based gene therapies

We are focused on developing disease-modifying therapies that address unmet medical needs of patients and families suffering from rare diseases with the goal of making a positive difference in their lives.

Matthew Gantz, President and Chief Executive Officer

Our robust development pipeline of personalized, targeted and redosable therapies

Leveraging our proprietary, autologous fibroblast technology platform

What's New

Press Release
Cell and Gene Therapy Innovator Castle Creek Biosciences Appoints Matthew Gantz as President and Chief Executive Officer

Life sciences executive brings more than 25 years of experience to cell and gene therapy company progressing through pivotal Phase 3 clinical trial

Read More
Media Coverage
Cell & Gene

Castle Creek Biosciences' D-Fi To Be Manufactured At In-House cGMP

Read More
Press Release
Castle Creek Biosciences Announces First Patient Dosed in DeFi-RDEB Phase 3 Clinical Trial of D-Fi Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Company manufacturing and distributing D-Fi at in-house, cGMP commercial-scale facility in greater Philadelphia area

Read More
Press Release
Castle Creek Biosciences Announces First Patient Dosed in Phase 1/2 Clinical Trial of FCX-013 Gene Therapy for Treatment of Moderate to Severe Localized Scleroderma

Study targets a chronic autoimmune skin disorder affecting approximately 50,000 patients in the U.S.

Read More